北京依生兴业科技有限公司 Yisheng Pharma
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023 2023-05-18 20:25
YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan 2023-05-16 19:00
YS Biopharma Announces Record Vaccine Revenues and Preliminary Financial Results for FY2023 Ended March 31, 2023 2023-04-18 19:00
YS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study 2023-03-27 18:00
YS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQ 2023-03-17 04:30
YS BIOPHARMA AND SUMMIT HEALTHCARE ANNOUNCE SHAREHOLDER APPROVAL OF BUSINESS COMBINATION 2023-03-15 04:01
SUMMIT HEALTHCARE ACQUISITION CORP. AND YS BIOPHARMA ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMENT AND EXTRAORDINARY GENERAL MEETING DATE FOR PROPOSED BUSINESS COMBINATION 2023-02-08 21:30
SUMMIT HEALTHCARE ACQUISITION CORP. AND YS BIOPHARMA ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMENT AND EXTRAORDINARY GENERAL MEETING DATE FOR PROPOSED BUSINESS COMBINATION 2023-02-08 21:30
YS Biopharma Received Qualified Person Declaration for Its PIKA COVID-19 Vaccine Facility Equivalent to European Union GMP 2022-11-16 08:50
YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 vaccine 2022-11-10 22:30
YS BIOPHARMA TO MERGE WITH NASDAQ-LISTED SUMMIT HEALTHCARE ACQUISITION CORP. 2022-09-30 04:01
YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recombinant COVID-19 vaccine 2022-09-08 21:33
YishengBio Announces PIKA recombinant COVID-19 vaccine received Phase I clinical trial IND clearance from New Zealand 2021-08-09 21:00
YishengBio Announces PIKA recombinant COVID-19 vaccine received Phase I clinical trial IND clearance from the UAE 2021-07-19 09:00
Yisheng Biopharma and Tavotek Biotherapeutics Announce Strategic Research Alliance for Development of YS-ON-001/002 and Tavo-301/303 Combination Therapy for Cancer Treatment 2020-01-06 09:00
Yisheng Biopharma Receives IND Clearance from China NMPA to Initiate Clinical Trial of YS-ON-001 in the Treatment of Advanced Solid Tumors 2019-06-27 09:00
Yisheng Biopharma Announces Research Presentation of Immuno-Oncology Product at AACR Annual Meeting 2019 2019-03-28 21:00
Yisheng Biopharma Announces Clearance from China FDA to Proceed with PIKA Rabies Vaccine Clinical Study 2018-10-08 21:00
Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia 2018-07-19 21:00
The US FDA Granted Orphan Drug Designation to Yisheng Biopharma's Biological Product for Pancreatic Cancer Treatment 2018-02-26 22:00
1 2 3 4